Monica Lövestam-Adrian

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3943587/publications.pdf

Version: 2024-02-01

		1163117	888059
17	340	8	17
papers	citations	h-index	g-index
17	17	17	530
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Association between diabetic eye disease and other complications of diabetes: Implications for care. A systematic review. Diabetes, Obesity and Metabolism, 2019, 21, 467-478.	4.4	110
2	Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic. Graefe's Archive for Clinical and Experimental Ophthalmology, 2020, 258, 1149-1156.	1.9	97
3	Treatment for neovascular ageâ€related macular degeneration in Sweden: outcomes at seven years in the Swedish Macula Register. Acta Ophthalmologica, 2017, 95, 787-795.	1.1	29
4	Macular function assessed with mfERG before and after panretinal photocoagulation in patients with proliferative diabetic retinopathy. Documenta Ophthalmologica, 2004, 109, 115-121.	2.2	19
5	CURRENT CONCEPTS AND MODALITIES FOR MONITORING THE FELLOW EYE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2020, 40, 599-611.	1.7	18
6	Baseline visual acuity as a prognostic factor for visual outcomes in patients treated with aflibercept for wet ageâ€related macular degeneration: data from the <scp>INSIGHT</scp> study using the Swedish Macula Register. Acta Ophthalmologica, 2019, 97, 91-98.	1.1	16
7	Anti-VEGF intravitreal injections in the era of COVID-19: responding to different levels of epidemic pressure. Graefe's Archive for Clinical and Experimental Ophthalmology, 2021, 259, 567-574.	1.9	14
8	Multifocal electroretinography amplitudes increase after photocoagulation in areas with increased retinal thickness and hard exudates. Acta Ophthalmologica, 2010, 88, 188-192.	1.1	10
9	Twelve per cent of 6142 eyes treated for neovascular ageâ€related macular degeneration (nAMD) presented with low visual outcome within 2Âyears. Analysis from the Swedish Macula Registry (SMR). Acta Ophthalmologica, 2020, 98, 274-278.	1.1	5
10	Vitrectomy Seems to be Beneficial for Advanced Diffuse Diabetic Macular Oedema not Responding to Laser Treatment. International Ophthalmology, 2006, 26, 21-26.	1.4	4
11	Multifocal Visual Evoked Potentials (mfVEP) in Diabetic Patients with and without Polyneuropathy. Open Ophthalmology Journal, 2012, 6, 98-103.	0.2	4
12	What about the fellow eye in treatment of neovascular ageâ€related macular degeneration? Analysis of data from the Swedish macula register. Acta Ophthalmologica, 2022, , .	1.1	4
13	No improvement in injection frequency or in visual outcome over time in two cohorts of patients from the same Swedish county treated for wet age-related macular degeneration. Clinical Ophthalmology, 2017, Volume 11, 1105-1111.	1.8	3
14	A novel tool to assess the quality of RWE to guide the management of retinal disease. Acta Ophthalmologica, 2021, 99, 604-610.	1.1	3
15	Treatment algorithm with dexamethasone intravitreal implant in patients with diabetic macular edema. Acta Ophthalmologica, 2020, 98, e528-e529.	1.1	2
16	Exploration of realâ€world outcomes and treatment patterns in patients treated with antiâ€vascular endothelial growth factors for neovascular ageâ€related macular degeneration in Sweden. Acta Ophthalmologica, 2021, , .	1.1	1
17	Electrophysiological evaluation and 18-month follow-up of two regimens with aflibercept for neovascular age-related macular degeneration. Documenta Ophthalmologica, 2022, , 1.	2.2	1